32 news items
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
BMY
CCCC
ONCY
28 May 24
will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics
yf611 cepyujmdb5o5c0i7k4pb5s6jt1owznjh6iob7
BMY
CCCC
ONCY
28 May 24
will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved
pa3nwu5s7hgrbt elj1ryq889a607rq3e9bq73fnvpz1
BMY
23 May 24
materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others
r144cvxwveye6csc4 tjholrpn8ucsu7vbcn0cjqs8lvgp7a2fa6p
BMY
16 May 24
and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include
hse6bans4o5n 9iemzc8b9rmanf8jhh
BMY
15 May 24
cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks
m7e0k8l0u3c1m604s1x03cu 0hdj9t2zuop3zzco
BMY
10 May 24
results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties
v8zhaod1w68r4be7gcz9qjg715agc49v7 6pot7h7oa
AAL
AAPL
ABBV
29 Apr 24
. On the other hand, healthcare, energy, and materials have reported year-over-year earnings declines.
See Also
wn6eaotnyh91z 67nceugd5p1uaphgn0p9s1
BMY
26 Apr 24
and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements
zh0e9725c20q7i6fsh35ffvrcapeyb8i3 rtyfcilg0su6snn0k
BMY
CVX
META
26 Apr 24
, health care and real estate stocks recording the biggest losses on Thursday. However, materials and emergy stocks bucked the overall market trend
gb3f9h7la4je421a1reiw116fa71ffj9
BMY
25 Apr 24
be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. See